Molecule
Eluxadoline is a mu-opioid receptor agonist indicated in adults for the treatment of irritable bowel syndrome with diarrhea (IBS-D). It is available as tablets for oral use. MedsAcross supplies Eluxadoline for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
VIBERZI is indicated in adults for the treatment of irritable bowel syndrome with diarrhea (IBS-D). VIBERZI is a mu-opioid receptor agonist, indicated in adults for the treatment of irritable bowel syndrome with diarrhea (IBS-D).
Source: US FDA prescribing information
Eluxadoline is a mu-opioid receptor agonist, eluxadoline is also a delta opioid receptor antagonist and a kappa opioid receptor agonist. The binding affinities (Ki) of eluxadoline for the human mu and delta opioid receptors are 1.8 nM and 430 nM, respectively. The binding affinity (Ki) of eluxadoline for the human kappa opioid receptor has not been determined, however, the Ki for guinea pig cerebellum kappa opioid receptor is 55 nM. In animals, eluxadoline interacts with opioid receptors in the gut.
Source: US FDA prescribing information
The recommended dosage of VIBERZI is 100 mg taken orally twice daily with food. The recommended dosage of VIBERZI is 75 mg taken orally twice daily with food in patients: unable to tolerate the 100 mg dose of VIBERZI. receiving concomitant OATP1B1 inhibitors. with mild (Child-Pugh Class A) or moderate (Child-Pugh Class B) hepatic impairment. with moderate or severe renal impairment (eGFR less than 60 mL/min/1.73 m 2 ), and in patients with end stage renal disease (ESRD) not yet on dialysis (eGFR less than 15 mL/min/1.73 m 2 ). Discontinue VIBERZI in patients who develop severe constipation. Instruct patients if they miss a dose, take the next dose at the regular time and not to take 2 doses at the same time to make up for a missed dose. The recommended dosage in adults is 100 mg twice daily taken with food.
Source: US FDA prescribing information
VIBERZI is contraindicated in patients: Without a gallbladder. These patients are at increased risk of developing serious adverse reactions of pancreatitis and/or sphincter of Oddi spasm With known or suspected biliary duct obstruction, or sphincter of Oddi disease or dysfunction. These patients are at increased risk for sphincter of Oddi spasm. With alcoholism, alcohol abuse or alcohol addiction, or in patients who drink more than 3 alcoholic beverages per day. These patients are at increased risk for acute pancreatitis. With a history of pancreatitis, or structural diseases of the pancreas, including known or suspected pancreatic duct obstruction.
Source: US FDA prescribing information
Pancreatitis and Sphincter of Oddi Spasm: Monitor patients for new or worsening abdominal pain, with or without nausea and vomiting, or acute biliary pain with liver or pancreatic enzyme elevations, immediately discontinue VIBERZI and seek medical attention if symptoms develop. Hypersensitivity Reactions, including anaphylaxis: Immediately discontinue VIBERZI and seek medical attention if symptoms develop. Constipation: Instruct patients to stop VIBERZI and immediately contact their healthcare provider if they develop severe constipation. Avoid use with other drugs that may cause constipation
Source: US FDA prescribing information
The following adverse reactions described below and elsewhere in the labeling include: Pancreatitis Sphincter of Oddi Spasm Hypersensitivity Reactions Constipation Most common adverse reactions (>5%) are constipation, nausea and abdominal pain.
Source: US FDA prescribing information
Tables 2 and 3 include drugs which demonstrated a clinically important drug interaction with VIBERZI or which potentially may result in clinically relevant interactions. Table 2: Established and Other Potentially Clinically Relevant Interactions Affecting VIBERZI OATP1B1 Inhibitors Clinical Impact: Increased exposure to eluxadoline when coadministered with cyclosporine Intervention: Administer VIBERZI at a dose of 75 mg twice daily and monitor patients for impaired mental or physical abilities needed to perform potentially hazardous activities such as driving a car or operating machinery and for other eluxadoline-related adverse reactions.
Source: US FDA prescribing information
Store VIBERZI tablets at 20°C to 25°C (68°F to 77°F) with excursions permitted to 15°C to 30°C (59°F to 86°F).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
2 presentations of Eluxadoline, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Viberzi 100 mg tabletOral | Allergan | US FDA | Available on request |
| Viberzi 75 mg tabletOral | Allergan | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Yes, on request. MedsAcross lists 2 presentations of Eluxadoline and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Eluxadoline, including Viberzi.
Yes. The US FDA first approved Eluxadoline on 27 May 2015, according to Drugs@FDA.
No listed presentation of Eluxadoline is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Eluxadoline is classified under ATC code A07DA06 (Eluxadoline).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.